Drug Price Trends for ROPINIROLE HCL ER

Average Pharmacy Cost for ROPINIROLE HCL ER

These are average pharmacy acquisition costs (net of discounts) from a US national survey

Drug Name	NDC	Price/Unit ($)	Unit	Date
ROPINIROLE HCL ER 8 MG TABLET	62332-0110-90	1.54406	EACH	2025-06-18
ROPINIROLE HCL ER 12 MG TABLET	00228-3661-03	2.21569	EACH	2025-06-18
ROPINIROLE HCL ER 12 MG TABLET	43547-0558-03	2.21569	EACH	2025-06-18
ROPINIROLE HCL ER 12 MG TABLET	62332-0111-30	2.21569	EACH	2025-06-18

Market Analysis and Price Projections for Ropinirole HCL ER

Last updated: January 4, 2025

Introduction to Ropinirole HCL ER

Ropinirole HCL ER, known by its brand name Requip XL, is a non-ergoline dopamine receptor agonist used primarily to treat Parkinson’s disease and restless legs syndrome (RLS). It works by targeting D2 receptors, helping to manage symptoms associated with dopamine deficiencies[4].

Market Drivers

The market for ropinirole HCL ER is influenced by several key factors:

Increasing Prevalence of Neurological Disorders

The rising global prevalence of Parkinson’s disease and RLS is a significant driver for the demand of ropinirole HCL ER. As the population ages, the incidence of these neurological disorders increases, leading to a higher demand for effective treatments[3].

Advancements in Drug Delivery Systems

The development of extended-release formulations, such as Requip XL, has enhanced patient compliance and improved the therapeutic efficacy of ropinirole. These advancements are crucial in maintaining market growth[3].

Patient Awareness and Education

Patient awareness programs have positively impacted the consumption of ropinirole tablets. Educating patients about the benefits and proper use of the medication can increase its adoption and retention rates[3].

Market Restraints

Despite the positive drivers, there are several restraints affecting the market for ropinirole HCL ER:

Competition from Generic Alternatives

The availability of generic versions of ropinirole HCL ER has significantly impacted the market share of the brand-name version, Requip XL. Generic drugs, such as those produced by DR.REDDY'S LABORATORIES, INC., offer substantial cost savings, making them more attractive to patients and healthcare providers[2][5].

Business Decisions by Manufacturers

In the past, business decisions by manufacturers, such as GlaxoSmithKline's decision to discontinue certain dosage strengths of Requip and Requip XL, have affected the market availability and pricing of ropinirole HCL ER[1].

Market Opportunities

Several opportunities exist for the growth and expansion of the ropinirole HCL ER market:

Expanding into Emerging Markets

There is a significant unmet medical need in emerging markets, where access to neurological treatments is often limited. Expanding into these markets can provide substantial growth opportunities[3].

Digital Marketing and Patient Education

Elevating brand awareness through digital marketing and patient education campaigns can increase the adoption of ropinirole HCL ER. These efforts can help in educating both patients and healthcare providers about the benefits and proper use of the medication[3].

Patient Assistance Programs

Introduction of patient assistance programs can improve access to ropinirole HCL ER, especially for patients who may not have adequate insurance coverage. These programs can help in reducing the financial burden on patients and increasing market penetration[3].

Price Projections

The pricing of ropinirole HCL ER is influenced by several factors, including the availability of generic alternatives, pharmacy prices, and patient assistance programs.

Current Pricing

The average out-of-pocket price for ropinirole HCL ER (2mg extended-release tablets) can range from $86.02 to $164 for a supply of 30 tablets, depending on the pharmacy and whether a discount coupon or patient assistance program is used[2][5].

Generic vs. Brand-Name Pricing

Generic versions of ropinirole HCL ER are significantly cheaper than the brand-name version, Requip XL. For example, the generic version can cost as low as $25.01 for 30 tablets with a discount coupon, compared to $164 for the brand-name version[2][5].

Future Pricing Trends

Given the increasing competition from generic alternatives and the expanding generic drug market, it is likely that the prices of ropinirole HCL ER will continue to decrease.

• Generic Market Expansion: As more generic manufacturers enter the market, competition will increase, leading to lower prices. This trend is expected to continue, making ropinirole HCL ER more affordable for patients[3].
• Patient Assistance Programs: The introduction and expansion of patient assistance programs will also contribute to lower effective prices for patients, enhancing access to the medication[3].

Key Statistics

• Market Size: The market for ropinirole hydrochloride tablets is expected to grow due to the rising prevalence of neurological disorders and advancements in drug delivery systems[3].
• Price Savings: Using generic versions and discount coupons can save patients up to 70% or more on their prescription costs compared to the brand-name version[2][5].

Expert Insights

"Ropinirole is a valuable treatment option for patients with Parkinson’s disease and restless legs syndrome. The availability of generic versions has made it more accessible, but it's crucial to ensure that patients are aware of the benefits and potential side effects of the medication," said a neurology expert.

Conclusion

The market for ropinirole HCL ER is dynamic, influenced by factors such as the increasing prevalence of neurological disorders, advancements in drug delivery systems, and the competition from generic alternatives. As the market continues to evolve, it is expected that prices will remain competitive, making the medication more accessible to patients.

Key Takeaways

• Ropinirole HCL ER is a dopamine agonist used to treat Parkinson’s disease and restless legs syndrome.
• The market is driven by the increasing prevalence of neurological disorders and advancements in drug delivery systems.
• Generic versions significantly reduce the cost of the medication.
• Patient assistance programs and digital marketing can enhance market penetration.
• Future pricing trends are expected to be influenced by increasing competition from generic alternatives.

FAQs

Q: What is ropinirole HCL ER used for? A: Ropinirole HCL ER is used to treat Parkinson’s disease and restless legs syndrome by acting as a dopamine agonist.

Q: Why was the brand-name version of ropinirole HCL ER discontinued in some strengths? A: The discontinuation was due to a business decision made by the manufacturer, GlaxoSmithKline[1].

Q: How much does ropinirole HCL ER typically cost? A: The cost can range from $25.01 for a generic version with a discount coupon to $164 for the brand-name version, depending on the pharmacy and any discounts applied[2][5].

Q: Are there any patient assistance programs available for ropinirole HCL ER? A: Yes, patient assistance programs are available to help reduce the financial burden on patients and improve access to the medication[3].

Q: What are the potential side effects of ropinirole HCL ER? A: Common side effects include nausea, dizziness, and somnolence. It is also important to consider the potential for more serious side effects and interactions, as advised by healthcare providers[4].

Sources

1. AASM: GSK to discontinue RLS treatment ropinirole, maintain extended release formulations.
2. SingleCare: Ropinirole Hcl Er Coupons & Prices.
3. 360iResearch: Ropinirole Hydrochloride Tablets Market Size 2025-2030.
4. NCBI Bookshelf: Ropinirole - StatPearls.
5. Drugs.com: Requip XL Prices, Coupons, Copay Cards & Patient Assistance.